- Home
- BGLC vs BFRI Comparison
BGLC vs BFRI Comparison
Compare BGLC & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- BFRI
- Stock Information
- Founded
- BGLC 2017
- BFRI 1997
- Country
- BGLC Malaysia
- BFRI United States
- Employees
- BGLC N/A
- BFRI N/A
- Industry
- BGLC Medical Specialities
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- BFRI Health Care
- Exchange
- BGLC Nasdaq
- BFRI Nasdaq
- Market Cap
- BGLC 5.8M
- BFRI 6.2M
- IPO Year
- BGLC N/A
- BFRI 2021
- Fundamental
- Price
- BGLC $0.38
- BFRI $1.10
- Analyst Decision
- BGLC
- BFRI Strong Buy
- Analyst Count
- BGLC 0
- BFRI 1
- Target Price
- BGLC N/A
- BFRI $7.00
- AVG Volume (30 Days)
- BGLC 10.9M
- BFRI 960.5K
- Earning Date
- BGLC 02-20-2025
- BFRI 03-14-2025
- Dividend Yield
- BGLC N/A
- BFRI N/A
- EPS Growth
- BGLC N/A
- BFRI N/A
- EPS
- BGLC N/A
- BFRI N/A
- Revenue
- BGLC $9,259,858.00
- BFRI $35,358,000.00
- Revenue This Year
- BGLC N/A
- BFRI $17.69
- Revenue Next Year
- BGLC N/A
- BFRI $19.71
- P/E Ratio
- BGLC N/A
- BFRI N/A
- Revenue Growth
- BGLC N/A
- BFRI 5.17
- 52 Week Low
- BGLC $0.21
- BFRI $0.61
- 52 Week High
- BGLC $3.39
- BFRI $2.43
- Technical
- Relative Strength Index (RSI)
- BGLC 59.27
- BFRI 53.42
- Support Level
- BGLC $0.33
- BFRI $0.97
- Resistance Level
- BGLC $0.41
- BFRI $1.11
- Average True Range (ATR)
- BGLC 0.11
- BFRI 0.16
- MACD
- BGLC 0.01
- BFRI -0.01
- Stochastic Oscillator
- BGLC 23.68
- BFRI 15.38
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.